Is your investment being diluted?
Enter a ticker. We read what the company filed and answer ten questions about the terms it agreed to. Every answer points to the document it came from.
Free. No account. Nothing here is investment advice, and no result says anyone did anything wrong.
The standard · amended 24 August 2026
Ten questions, asked the same way every time
Each one is answered from a document the company filed. The questions are fixed before any company is looked at, so the answer cannot be steered by what would make a better story. Four of them were added on 24 August 2026 after a company came back nearly clean on the first six and the exhibit turned out to say otherwise. The method page records what changed and why.
| # | The question | What fails it |
|---|---|---|
| Loading the tests… | ||
A test that cannot apply to an instrument is marked n/a, not counted as a failure. A convertible note has no warrant coverage; a share placement has no blocker. No company is scored above flagged until someone has read the exhibit itself — not the 8-K summary of it.
Detected
Companies whose filings failed one or more tests
Each row links to the filing it came from. The outcome columns record what happened afterward, whichever way it went.
| Ticker | Instrument | Event | Failed | 90 days | 1 year | Since | |
|---|---|---|---|---|---|---|---|
| Loading… | |||||||
Cleared
Companies we looked at that came back clean
A screen that can only ever produce a finding is not a screen. These are on the page for the same reason as everything else — because that is what the filings said.
| Ticker | Instrument | Event | Failed | 1 year | Why it cleared |
|---|---|---|---|---|---|
| Loading… | |||||
Standing disclosure
Where the author stands
A numbered archive of securities research assembled from primary sources — SEC filings, FINRA data, corporate records demands, and correspondence. Every figure here carries instructions for reproducing it. Nothing on this site asks the reader to take the author's word for anything.
Position. The author holds shares of Theriva Biologics, Inc. (NYSE American: TOVX) and has held them for more than four years. The author formerly held shares of iBio, Inc. (IBIO) and sold that position at a profit.
No allegation of wrongdoing. These reports describe transactions that were disclosed in filings made with the Securities and Exchange Commission. Representing issuers in registered offerings, acting as placement agent, and serving on a board of directors are lawful activities. No report on this site alleges that any person or firm has broken any law.
Triggered Short™ is the author's own descriptive term for a financing pattern. It is not an established legal, regulatory, or accounting concept.
Reports
The written work
Where a company has been researched in full, the reports carry the evidence and the correspondence. Each one names its subject and stands on its own.
Reproduce it yourself
Every ownership figure in this docket came from the same free tool. It takes about ten minutes.
- Open sec.gov/edgar/search — the SEC's full-text search, covering electronic filings since 2001.
- Type a name in quotation marks and press Search. For example:
"Empery Asset Management" - On the results page, open the Entity panel on the left. It lists every filer whose documents contain that phrase, with a count for each.
- Use Show Columns → Incorporated to add each issuer's state or country of incorporation to the results table.